Is a
Patent attributes
Patent Jurisdiction
Patent Number
Patent Inventor Names
Sang Jae Kim0
Date of Patent
August 20, 2019
0Patent Application Number
148963580
Date Filed
June 5, 2014
0Patent Citations Received
Patent Primary Examiner
Patent abstract
Methods are disclosed that are based on the finding that serum and plasma levels of eotaxin, MIP1α, and CRP act as important biomarkers that are useful for determining the feasibility in instigating immunotherapeutic treatment of cancer when immunizing with the GV1001 peptide (EARPALLTSRLRFIPK; derived from human telomerase protein), optionally when combined with state of the art combination treatment with Gemcitabine and Capecitabine. In particular, the present invention provides methods for determining whether patients should be treated GV1001 and for determining whether instigated treatment should be continued.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
